JP7613580B2 - 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩 - Google Patents

抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩 Download PDF

Info

Publication number
JP7613580B2
JP7613580B2 JP2023525901A JP2023525901A JP7613580B2 JP 7613580 B2 JP7613580 B2 JP 7613580B2 JP 2023525901 A JP2023525901 A JP 2023525901A JP 2023525901 A JP2023525901 A JP 2023525901A JP 7613580 B2 JP7613580 B2 JP 7613580B2
Authority
JP
Japan
Prior art keywords
group
formula
same
bond
divalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023525901A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022255425A1 (https=
JPWO2022255425A5 (https=
Inventor
豊 松田
友博 藤井
竜介 平間
トーマス マルコタン
アラン プライア
クリストファー ウォン
コンスタンティノ プラカス
友博 渡部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPWO2022255425A1 publication Critical patent/JPWO2022255425A1/ja
Publication of JPWO2022255425A5 publication Critical patent/JPWO2022255425A5/ja
Priority to JP2024231090A priority Critical patent/JP2025060910A/ja
Application granted granted Critical
Publication of JP7613580B2 publication Critical patent/JP7613580B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023525901A 2021-06-01 2022-06-01 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩 Active JP7613580B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231090A JP2025060910A (ja) 2021-06-01 2024-12-26 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195448P 2021-06-01 2021-06-01
US63/195,448 2021-06-01
US202263312489P 2022-02-22 2022-02-22
US63/312,489 2022-02-22
PCT/JP2022/022393 WO2022255425A1 (ja) 2021-06-01 2022-06-01 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231090A Division JP2025060910A (ja) 2021-06-01 2024-12-26 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩

Publications (3)

Publication Number Publication Date
JPWO2022255425A1 JPWO2022255425A1 (https=) 2022-12-08
JPWO2022255425A5 JPWO2022255425A5 (https=) 2024-02-01
JP7613580B2 true JP7613580B2 (ja) 2025-01-15

Family

ID=84324131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023525901A Active JP7613580B2 (ja) 2021-06-01 2022-06-01 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩
JP2024231090A Pending JP2025060910A (ja) 2021-06-01 2024-12-26 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231090A Pending JP2025060910A (ja) 2021-06-01 2024-12-26 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩

Country Status (7)

Country Link
US (1) US20240165260A1 (https=)
EP (1) EP4349373A1 (https=)
JP (2) JP7613580B2 (https=)
KR (1) KR20240016287A (https=)
AU (1) AU2022286137A1 (https=)
CA (1) CA3222015A1 (https=)
WO (1) WO2022255425A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813388A (zh) * 2023-03-02 2025-10-17 日本医事物理股份有限公司 放射性金属标记抗体、放射性药物及化合物
WO2026054053A1 (ja) * 2024-09-05 2026-03-12 日本メジフィジックス株式会社 修飾抗体、放射性金属標識抗体及び放射性医薬

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
JP2016534990A (ja) 2013-10-15 2016-11-10 シアトル ジェネティックス， インコーポレイテッド 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019231879A1 (en) 2018-05-29 2019-12-05 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
JP2019536765A (ja) 2016-11-08 2019-12-19 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
WO2019240288A1 (ja) 2018-06-14 2019-12-19 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
JP2021502341A (ja) 2017-11-07 2021-01-28 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗体薬物コンジュゲートのための親水性リンカー

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3185908T3 (pl) 2014-08-28 2020-09-07 Pfizer Inc. Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek
HK1243931A1 (zh) 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
AU2018259856B2 (en) 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
JPWO2019093495A1 (ja) * 2017-11-10 2020-11-26 株式会社明治 たんぱく質検出法
KR102921757B1 (ko) * 2018-06-14 2026-02-03 아지노모토 가부시키가이샤 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN113853219B (zh) * 2019-05-20 2025-01-07 诺华股份有限公司 具有包含亲水性基团的接头的抗体药物缀合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
JP2016534990A (ja) 2013-10-15 2016-11-10 シアトル ジェネティックス， インコーポレイテッド 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー
JP2019536765A (ja) 2016-11-08 2019-12-19 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
JP2021502341A (ja) 2017-11-07 2021-01-28 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗体薬物コンジュゲートのための親水性リンカー
WO2019231879A1 (en) 2018-05-29 2019-12-05 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
WO2019240288A1 (ja) 2018-06-14 2019-12-19 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF

Also Published As

Publication number Publication date
WO2022255425A1 (ja) 2022-12-08
JPWO2022255425A1 (https=) 2022-12-08
EP4349373A1 (en) 2024-04-10
AU2022286137A2 (en) 2024-01-11
JP2025060910A (ja) 2025-04-10
KR20240016287A (ko) 2024-02-06
AU2022286137A1 (en) 2023-12-14
US20240165260A1 (en) 2024-05-23
CA3222015A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JPWO2019240288A1 (ja) 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
JP2025060910A (ja) 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩
JP7658450B2 (ja) 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
WO2024210154A1 (ja) 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
JP2025111561A (ja) 化合物またはその塩、およびそれらにより得られる抗体
US20240285788A1 (en) Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
WO2024210178A1 (ja) 抗体および機能性物質のコンジュゲートまたはその塩、ならびにチオール基を有する抗体中間体またはその塩
CN117412774A (zh) 抗体和功能性物质的缀合物或其盐、以及其制造中使用的化合物或其盐
JP2024010532A (ja) 化合物またはその塩
CN118119639A (zh) 抗体和功能性物质的缀合物或其盐、以及其制造中使用的抗体衍生物和化合物或它们的盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231130

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240612

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241209

R150 Certificate of patent or registration of utility model

Ref document number: 7613580

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150